Observational look at how adults with stomach and GEJ cancer are diagnosed and treated in Greece

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, Greece-only observational study collects retrospective and prospective data to describe epidemiology and management patterns of stage II-IVB gastric/GEJ adenocarcinoma in routine clinical care. It is non-interventional and seeks to document outcomes as patients undergo standard treatment chosen by their clinicians. Participation is voluntary and can be withdrawn at any time, with efforts made to capture outcomes. The study is sponsored by AstraZeneca and involves several Greek research sites. Data collection spans from June 1, 2025 through the end of the recruitment period in Q3 2027.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients aged ≥18 years upon gastric/GEJ adenocarcinoma diagnosis.
* Written signed and dated informed consent by the patient (or their legally acceptable representative, as applicable). For deceased patients on the date of study entry a waiver of consent must be approved by the Hospital EC/IRB.
* Patients diagnosed with histologically confirmed, stage II to IVB adenocarcinoma of gastric/GEJ, between June 1st, 2025 and the end of the recruitment period (Q3 2027).

Exclusion Criteria:

* Patients who participate or participated during the data collection period (prospective and retrospective) in any clinical investigation/clinical trial that includes interventions that fall outside the everyday clinical practice.
* Patients who have participated in the design and/or the conduct of the study.
* Patients with another primary malignancy within the last 5 years, for which systemic anticancer treatment is required after the diagnosis of gastric/GEJ cancer.

Where it's running

• Research Site
  Athens, Greece Recruiting
• Research Site
  Crete, Greece Recruiting
• Research Site
  Thessaloniki, Greece Recruiting
• Research Site
  Alexandroupoli, Greece Not yet recruiting
• Research Site
  Athens, Greece Not yet recruiting
• Research Site
  Athens, Greece Withdrawn

Study contacts

• Study coordinator: AstraZeneca Clinical Study Information Center
• Email: information.center@astrazeneca.com
• Phone: 877-240-9479

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer

  This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07818018

• Comprehensive Prehabilitation Program for Locally Advanced Esophagogastric Cancer

  This trial tests if a personalized prehabilitation plan with nutrition, exercise, and psychological support helps patients with locally advanced esophageal, GEJ, or gastric cancer before surgery.

  Recruiting Masaryk Memorial Cancer Institute · Brno · NCT07671625

• Cadonilimab with chemotherapy for gastric or GEJ cancer

  This trial tests whether adding cadonilimab to standard chemotherapy is safe and effective for adults with locally advanced or resectable gastric or GEJ cancer.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07631000

• Adebrelimab with SHR-A1811/SHR-A1904 plus chemotherapy or with SHR-8068 for gastric and gastroesophageal-junction cancer

  This trial tests whether adding Adebrelimab to SHR-A1811 or SHR-A1904 plus chemotherapy, or combining Adebrelimab with SHR-8068, improves outcomes for adults newly diagnosed with gastric or gastroesophageal-junction cancer who have not yet received treatment.

  Recruiting at 2 sites Phase 2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Shijiazhuang, Hebei and 1 other locations · NCT07110571

• DR-0202 for advanced, relapsed, or treatment-resistant carcinomas

  This trial tests DR-0202 in adults with advanced or metastatic carcinomas—such as certain breast, lung, cervical, and prostate cancers—that have relapsed or stopped responding to standard treatments.

  Recruiting at 10 sites Phase 1 Dren Bio · Denver, Colorado and 9 other locations · NCT06999187

• Combination treatment for advanced HER2-positive gastric cancer

  This study is testing a new combination treatment for adults with advanced HER2-positive gastric cancer to see if it works better than the standard treatment.

  Recruiting at 219 sites Phase 3 Daiichi Sankyo · New Haven, Connecticut and 249 other locations · NCT06731478

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.